Robert J. Vanner

Toronto, ON, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

The role of stereotactic body radiotherapy in the management of hepatocellular carcinoma with macroscopic vascular invasion: a narrative review.

The role of stereotactic body radiotherapy in the management of hepatocellular carcinoma with macroscopic vascular invasion: a narrative review.

Journal: ESMO gastrointestinal oncology

Published: April 17, 2026

Under pressure: clonal hematopoiesis in patients receiving cancer therapy.

Under pressure: clonal hematopoiesis in patients receiving cancer therapy.

Journal: Trends in cancer

Published: March 31, 2026

Stereotactic body radiotherapy treatment for hepatocellular carcinoma with extensive macrovascular invasion.

Stereotactic body radiotherapy treatment for hepatocellular carcinoma with extensive macrovascular invasion.

Journal: Journal of hepatology

Published: September 04, 2025

Clinical decisions in clonal hematopoiesis: a contemporary review for clinicians.

Clinical decisions in clonal hematopoiesis: a contemporary review for clinicians.

Journal: Haematologica

Published: August 27, 2025

Heart Failure Post-Hematopoietic Cell Transplantation in Patients With Lymphoma: Another Piece of the CHIP Puzzle.

Heart Failure Post-Hematopoietic Cell Transplantation in Patients With Lymphoma: Another Piece of the CHIP Puzzle.

Journal: JACC. CardioOncology

Published: February 03, 2025

Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors.

Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors.

Journal: Cancer research communications

Published: October 31, 2024

Inflammatory reprogramming of the solid tumor microenvironment by infiltrating clonal hematopoiesis is associated with adverse outcomes.

Inflammatory reprogramming of the solid tumor microenvironment by infiltrating clonal hematopoiesis is associated with adverse outcomes.

Journal: Cell reports. Medicine

Published: September 16, 2024

Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation.

Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation.

Journal: Cancer research

Published: September 12, 2024

TET2 deficiency increases the competitive advantage of hematopoietic stem and progenitor cells through upregulation of thrombopoietin receptor signaling.

TET2 deficiency increases the competitive advantage of hematopoietic stem and progenitor cells through upregulation of thrombopoietin receptor signaling.

Journal: Nature communications

Published: March 22, 2024

OLIG2 mediates a rare targetable stem cell fate transition in sonic hedgehog medulloblastoma.

OLIG2 mediates a rare targetable stem cell fate transition in sonic hedgehog medulloblastoma.

Journal: Nature communications

Published: May 18, 2023

Multiomic Profiling of Central Nervous System Leukemia Identifies mRNA Translation as a Therapeutic Target.

Multiomic Profiling of Central Nervous System Leukemia Identifies mRNA Translation as a Therapeutic Target.

Journal: Blood cancer discovery

Published: December 03, 2020

Relapse-Fated Latent Diagnosis Subclones in Acute B Lineage Leukemia Are Drug Tolerant and Possess Distinct Metabolic Programs.

Relapse-Fated Latent Diagnosis Subclones in Acute B Lineage Leukemia Are Drug Tolerant and Possess Distinct Metabolic Programs.

Journal: Cancer discovery

Published: September 11, 2019

Showing 1-12 of 24

Last Updated: 09/26/2026